Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study

Vault CDMS to manage clinical data for trial involving Barrett's esophagus and esophageal adenocarcinoma patients PLEASANTON, Calif., May 4, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage, cancer prevention...

Click to view original post